SCHEMBL4284029

SCHEMBL4284029

Cc1cc(Nc2ncc3ccn(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3n2)cnc1N1CC(C)NC(C)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 2/20 0.47
STAT6 P42226 6/20 0.42
JAK2 O60674 9/20 0.40
BRD4 O60885 9/20 0.40
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCND2 P30279 1/20 0.37
CCND3 P30281 1/20 0.37
JAK1 P23458 1/20 0.37
BRD2 P25440 1/20 0.37
JAK3 P52333 1/20 0.37
BRD3 Q15059 1/20 0.37
BRDT Q58F21 1/20 0.37
TTK P33981 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284027 1.00 RPS6KA3 (0.47) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4288402 0.93 RPS6KA3 (0.47) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4288398 0.93 RPS6KA3 (0.47) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4283802 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4285172 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4295376 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4295373 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4283806 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4285169 0.91 RPS6KA3 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL1655245 0.90 RPS6KA3 (0.42) RPS6KA3STAT6JAK2BRD4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US claimed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US claimed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885STAT6 601/4885JAK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.